- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02027662
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules (OsvaRenNEW)
Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced.
This study is about efficacy and safety of the new drug formulation and compares it to the "old" formulation which are film-coated tablets.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is aimed at demonstrating the therapeutic equivalence of both products, i.e. granules versus tablets.
Secondary objectives are: Comparing both preparations with regard to the number of patients reaching serum phosphate levels < 1.76 mmol/L and the difference in serum phosphate levels between the first and last visit under each treatment. Furthermore, it is the aim of this study to evaluate the safety profile of OsvaRen® granules in comparison to OsvaRen® tablets. Especially serum calcium, magnesium, and PTH are of interest.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Erfurt, Germany
- Nephro-Studien GbR am Klinikum Erfurt
-
Flensburg, Germany, 24939
- Dialysezentrum
-
Hamburg, Germany, 22297
- Nephrocare Hamburg-Barmbek GmbH
-
Hannover, Germany
- Dialysezentrum
-
Kiel, Germany, 24106
- Dialysezentrum
-
Magdeburg, Germany
- Dialysezentrum
-
Minden, Germany
- Dialysezentrum
-
Solingen, Germany
- Dialysezentrum
-
Velbert, Germany
- Dialysezentrum
-
-
Hessen
-
Giessen, Hessen, Germany, 35392
- Georg-Haas-Dialysezentrum der PHV
-
-
NRW
-
Aachen, NRW, Germany, 52074
- RWTH University Hospital, Dpt for Nephrology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent form is obtained prior to starting the screening visit
- Male and female patients 18-80 years of age with dialysis dependent renal failure (CKD 5D)
Patients have been on 3x/week in-centre renal replacement therapy for at least 2 months on either low-flux or high-flux HD or OL-
/HDF
- Prescribed haemodialysis session duration is ≥ 4 hours
- spKt/V ≥ 1.20 according to last in-centre measurement prior the study enrolment
- Patients have been on OsvaRen® tablets for at least 12 weeks as sole phosphate binder and the titration phase has been completed according to physician´s discretion
- Patients are able to take the study medication as prescribed particularly OsvaRen® stickpacks
- Patients are willing to stop any calcium, magnesium or vitamin D containing supplements
- Patients are willing to maintain their typical diet with regards to phosphate uptake for the time of the study
- Patients are willing to comply with the study protocol
Exclusion criteria
- Pregnant women (by blood ß-hCG pregnancy test) or women breast-feeding or unwilling to use contraceptive measures during the entire course of the study or
- Patients with a life expectancy shorter than the planned duration of the study or
- Patients with any acute or chronic severe disease potentially interfering with study outcomes or
- Patients with PTH levels > 800 ng/l or
- Patients who participated in an interventional clinical study during the preceding 30 days or
- Patients suffering from any other, not mentioned condition which could interfere with the patient's ability to comply with the study or
- Patients who previously participated in the same study are excluded from the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Osvaren Granules
|
|
ACTIVE_COMPARATOR: Osvaren film-coated tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Non-inferiority of phosphate control by granules versus tablets. Serum phosphate levels will be measured for the primary outcome.
Time Frame: After 4 weeks of treatment time
|
After 4 weeks of treatment time
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients reaching serum phosphate levels < 1.76 mmol/L. this study to evaluate the safety profile of OsvaRen® granules. in comparison to OsvaRen® tablets. Especially serum calcium, magnesium, and PTH are of interest.
Time Frame: Between the first and last visit under each treatment i.e. 4 weeks
|
Between the first and last visit under each treatment i.e. 4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jürgen Floege, MD, University Aachen
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-OSV-02-D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Osvaren Granules
-
Bing ShuHuadong Hospital; Longhua Hospital; The First Affiliated Hospital of Anhui University...WithdrawnRenal Insufficiency, Chronic | Renal OsteodystrophyChina
-
Shanghai Jiao Tong University School of MedicineShijiazhuang Yiling Pharmaceutical Co. LtdUnknown
-
Tasly Pharmaceutical Group Co., LtdNot yet recruiting
-
Smilebiotek Zhuhai LimitedRecruitingIntermediate Age-Related Macular DegenerationChina
-
Peking Union Medical College HospitalActive, not recruiting
-
Children's Hospital of Fudan UniversityCompletedPrecocious PubertyChina
-
Chinese University of Hong KongRecruiting
-
West China HospitalXiamen Health Commission; Xiamen Health and Medical Big Data CenterActive, not recruitingPregnancy | Birth Defects | Drug ExposuresChina
-
Shanghai Yueyang Integrated Medicine HospitalBeijing Hospital of Traditional Chinese Medicine; First Affiliated Hospital... and other collaboratorsUnknownPsoriasis VulgarisChina
-
Shanghai Yueyang Integrated Medicine HospitalHeilongjiang University of Chinese Medicine; The Affiliated Hospital of Jiangxi... and other collaboratorsUnknownPsoriasis VulgarisChina